Houston, TX -- (SBWIRE) -- 06/21/2018 -- Research N Reports has announced the addition of a new market intelligence report. The report is titled, "United States Prostate Cancer Diagnostics Market By Manufacturers, States, Type And Application, Forecast To 2022". The report comprises of the market growth figures since last few years and the estimated growth trajectory for the coming future. The prostate cancer diagnostics market is expected to witness a CAGR of +6.3% during the forecast period (2018-2022). North America was leading the global market with the largest revenue share in 2017.
The high prevalence of prostate cancer is a key factor in the global market for prostate cancer. Prostate cancer is the second leading cause of death in the United States. According to the National Cancer Institute, a total of 161,360 new prostate cancer patients are estimated to die, resulting in 26,730 deaths. Based on these statistics, we can see that the prevalence of prostate cancer is increasing worldwide and is leading the market.
Other factors include drug innovation, genomics and proteomics development, public and private funding, drug development, and oncology diagnostic and therapeutic advances.

For sample copy of this report: https://www.researchnreports.com/request_sample.php?id=64813

There are many new drugs approved by the Food & Drug Administration that increase the life expectancy of patients with prostate cancer. However, these drugs are at a high cost that threatens both the patient and the insurance company. These expensive drugs are not paid by insurance companies and the level of reimbursement for them is very low. Therefore, only a small number of people can get medication. As a result, the cost of generics is increasing, and this is hindering the growth of the prostate cancer therapeutic market.

Market Segment by Manufacturers, this report covers
Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, bioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics

Market Segment by States, covering
California
Texas
New York
Florida
Illinois

Market Segment by Type, covers
Tumor Biomarker Tests
Imaging
Biopsy

Avail discount on this report: https://www.researchnreports.com/ask_for_discount.php?id=64813

The Major players reported in the market include:
Bruker Daltonics, Abbott, Agilent, BDI, OncoThyreon, Biomoda, Asuragen, Beckman Coulter, BioCurex
North America is the leading global market with the largest revenue share in 2017. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region, due to the improving healthcare infrastructure and the growing investments by the key market players.
February 2017: AstraZeneca has signed an agreement with TerSera Therapeutics LLC at Zoladex in the US and Canada. Zoladex is an injectable luteinizing hormone releasing agent used to treat prostate cancer, breast cancer and certain benign gynecological diseases.

For Any Query on Prostate Cancer Diagnostics market report, Speak to Industry Expert at: https://www.researchnreports.com/enquiry_before_buying.php?id=64813